Related Experiment Video
Updated: Jun 10, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Management of Fabry disease]
Tamás Constantin1, Annamária Székely, Andrea Ponyi
1Semmelweis Egyetem, Altalános Orvostudományi Kar II. Gyermekgyógyászati Klinika Budapest Tuzoltó u. 7-9. 1094.
Abstract:
Fabry disease is a rare, X-linked lysosomal storage disorder that leads to accumulation of globotriaosylceramide in different tissues of the body. The disease is progressive and the first symptoms usually present in childhood. Consequences of the disease are disability and premature death. The disease in females could be as severe as in males although women may be asymptomatic. The possibility of enzyme replacement therapy has made it necessary to elaborate a comprehensive guideline for the diagnosis and treatment follow-up. The guideline has been summarized by a Hungarian multi-disciplinary working group consisting of physicians who are involved in diagnosis and care of Fabry patients. Previous clinical studies, published articles, and recently established international treatment guidelines were reviewed by the group.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Mitral Stenosis III: Medical Management
Atherosclerosis IV: Nursing Management
